Abivax SA
PAR:ABVX

Watchlist Manager
Abivax SA Logo
Abivax SA
PAR:ABVX
Watchlist
Price: 116 EUR -5.23% Market Closed
Market Cap: 9B EUR

Relative Value

There is not enough data to reliably calculate the relative value of ABVX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ABVX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
Forward
814.1
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-14.1
Industry
23.7
Forward
-43.8
vs History
vs Industry
Median 3Y
-10.1
Median 5Y
-21
Industry
22
vs History
vs Industry
Median 3Y
-10.4
Median 5Y
-19.3
Industry
24.3
vs History
vs Industry
28
Median 3Y
5.9
Median 5Y
5.9
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.2
Forward
801.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
vs History
vs Industry
Median 3Y
-8.7
Median 5Y
-16.5
Industry
6.1
Forward
-46.4
vs History
vs Industry
Median 3Y
-8.6
Median 5Y
-16.3
Industry
6.5
Forward
-46.5
vs History
vs Industry
Median 3Y
-9.4
Median 5Y
-19.6
Industry
7.9
vs History
vs Industry
Median 3Y
-9.4
Median 5Y
-19.4
Industry
6.3
vs History
vs Industry
21
Median 3Y
23
Median 5Y
39.4
Industry
5.7

Multiples Across Competitors

ABVX Competitors Multiples
Abivax SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Abivax SA
PAR:ABVX
9.4B EUR 0 -39.5 -42.3 -42
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 766 261.7 -160 486 -194 881.2 -192 657.4
US
Abbvie Inc
NYSE:ABBV
406.4B USD 6.8 172.7 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
177B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
153.1B USD 5.2 18.8 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 9.8 31.4 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.4 -532.4 -579.7 -564.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.5B USD 5.7 17.8 17 19.3
AU
CSL Ltd
ASX:CSL
83.6B AUD 3.6 18.6 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD 16.4 1 206.2 162.6 197.3
NL
argenx SE
XBRU:ARGX
43.8B EUR 14.3 33.6 57.9 59.5
P/S Multiple
Revenue Growth P/S to Growth
FR
Abivax SA
PAR:ABVX
Average P/S: 3 376 841.5
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 766 261.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 086.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.3
49%
0.3
P/E Multiple
Earnings Growth PEG
FR
Abivax SA
PAR:ABVX
Average P/E: 190.5
Negative Multiple: -39.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 486 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.8
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 206.2
N/A N/A
NL
argenx SE
XBRU:ARGX
33.6
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Abivax SA
PAR:ABVX
Average EV/EBITDA: 40.1
Negative Multiple: -42.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 881.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.6
N/A N/A
NL
argenx SE
XBRU:ARGX
57.9
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Abivax SA
PAR:ABVX
Average EV/EBIT: 46.3
Negative Multiple: -42
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 657.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197.3
N/A N/A
NL
argenx SE
XBRU:ARGX
59.5
N/A N/A